ストックスクリーナーアプリを入手
5.92
27.31%
1.27
アフターアワーズ：
5.60
-0.32
-5.41%
Karyopharm Therapeutics Inc (KPTI) 最新ニュース
What are Karyopharm Therapeutics Inc.’s recent SEC filings showingMarket Risk Report & Reliable Entry Point Alerts - thegnnews.com
Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Shares Bounce 42% But Its Business Still Trails The Industry - 富途牛牛
Can Karyopharm Therapeutics Inc. rally from current levelsWeekly Profit Analysis & Technical Pattern Recognition Alerts - Newser
Karyopharm Therapeutics Inc. stock prediction for this weekTrade Volume Report & Free Weekly Chart Analysis and Trade Guides - Newser
Advanced analytics toolkit walkthrough for Karyopharm Therapeutics Inc.Portfolio Profit Report & Verified Momentum Stock Alerts - Newser
How to read the order book for Karyopharm Therapeutics Inc.July 2025 Drop Watch & Capital Protection Trading Alerts - Newser
Published on: 2025-08-16 03:21:01 - Newser
Comparing Karyopharm Therapeutics Inc. in custom built stock radarsWeekly Market Report & Safe Capital Preservation Plans - Newser
How moving averages guide Karyopharm Therapeutics Inc. tradingPortfolio Gains Summary & Free Community Supported Trade Ideas - Newser
Is a relief rally coming for Karyopharm Therapeutics Inc. holders2025 Support & Resistance & Risk Controlled Swing Alerts - Newser
What makes Karyopharm Therapeutics Inc. stock attractive to long term investorsM&A Rumor & Safe Investment Capital Preservation Plans - Newser
Karyopharm’s Earnings Call: Clinical Wins Amid Financial Strain - MSN
Why Karyopharm Therapeutics Inc. stock attracts strong analyst attention2025 Bull vs Bear & AI Powered Market Trend Analysis - Newser
US$25.92: That's What Analysts Think Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Is Worth After Its Latest Results - simplywall.st
Karyopharm Therapeutics’ SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates - MSN
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q2 2025 Earnings Call Transcript - Insider Monkey
Karyopharm Therapeutics (NASDAQ:KPTI) Given New $25.00 Price Target at Robert W. Baird - Defense World
Karyopharm Therapeutics shares rise 1.03% premarket after reporting Q2 earnings. - AInvest
Karyopharm Therapeutics Inc. Builds Base for Possible ReboundOversold Bounce Stock Play Ideas Gain Attention - beatles.ru
Baird Lowers Karyopharm PT to $25 from $42 Amid Patent Concerns - AInvest
Karyopharm Therapeutics Reports Q2 Loss Amid Revenue ShortfallNews and Statistics - IndexBox
Karyopharm Therapeutics: Q2 Earnings Snapshot - CTPost
Karyopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Call Highlights: Navigating Financial ... - Yahoo Finance
Karyopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Call Highlights: Navigating Financial ... By GuruFocus - Investing.com Canada
Will Karyopharm Therapeutics Inc. see short term momentumFree Momentum Based Equity Trading Plan - Newser
Karyopharm Therapeutics Reports Q2 2025 Earnings - TipRanks
Karyopharm’s Revenue Dips As Drug Sales Inch Upward - Finimize
Karyopharm Sees Mixed Q2 As XPOVIO Sales Climb - Finimize
Karyopharm outlines $1B peak U.S. revenue opportunity in myelofibrosis with pivotal Phase III data expected by March 2026 - MSN
Karyopharm Therapeutics Sees $1B Peak Revenue Potential in Myelofibrosis by 2026 - AInvest
Karyopharm Reports Q2 2025 Financial Results, Updates Guidance, and Explores Financing and Strategic Alternatives - AInvest
Karyopharm Therapeutics Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:KPTI) - Seeking Alpha
Earnings call transcript: Karyopharm Q2 2025 sees revenue decline amid strategic shifts - Investing.com
Karyopharm Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Karyopharm Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Transcript : Karyopharm Therapeutics Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress - Citizen Tribune
Karyopharm Q2 2025 slides: Myelofibrosis pivot amid mixed financial results By Investing.com - Investing.com Nigeria
Karyopharm Q2 2025 slides: Myelofibrosis pivot amid mixed financial results - Investing.com
Karyopharm Therapeutics Q2 revenue falls 11% - MarketScreener
Karyopharm Therapeutics Inc. SEC 10-Q Report - TradingView
Karyopharm Therapeutics Q2 EPS Misses Estimate, Revenue Down 11.4% Y/Y - AInvest
Karyopharm Q2 rev. $37.9mln, up 6% YoY; updates FY guidance. - AInvest
Multi Factor Analysis Ranks Karyopharm Therapeutics Inc. as Strong BuyMomentum Based Equity Trading Plans Reviewed - beatles.ru
Karyopharm Reports Second Quarter 2025 Financial Results and Hig - GuruFocus
What makes Karyopharm Therapeutics Inc. stock price move sharplyValue Investing Checklist with Entry Signals - Newser
Layoff Tracker: Bicycle, Tune, Iovance, Precision Downsize to Conserve Cash - BioSpace
Earnings Outlook For Karyopharm Therapeutics - 富途牛牛
Visual trend scoring systems applied to Karyopharm Therapeutics Inc.Technical Reversal Setup with Risk Limits - Newser
Automated trading signals detected on Karyopharm Therapeutics Inc.Free Community Strategy With High Win Rate - Newser
Chart based exit strategy for Karyopharm Therapeutics Inc.Secure Entry Point Finder with Analysis - Newser
Karyopharm Therapeutics shares rise 1.78% after-hours following Bicycle Therapeutics' board expansion. - AInvest
Karyopharm Therapeutics Inc expected to post a loss of $4.10 a shareEarnings Preview - TradingView
0.41%
0.88%
大文字化:
|
ボリューム (24 時間):